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Abstract: Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease 
of the lung caused primarily by exposure to cigarette smoke. Clinically, it presents with progres-
sive cough, sputum production, dyspnea, reduced exercise capacity, and   diminished quality of 
life. Physiologically, it is characterized by the presence of partially reversible expiratory airflow 
limitation and hyperinflation. Pathologically, COPD is a multicomponent disease characterized 
by bronchial submucosal mucous gland hypertrophy, bronchiolar mucosal hyperplasia, increased 
luminal inflammatory mucus, airway wall inflammation and scarring, and alveolar wall damage 
and destruction. Management of COPD involves both pharmacological and   nonpharmacological 
approaches. Bronchodilators and inhaled corticosteroids are recommended medications for 
management of COPD especially in more severe disease. Combination therapies containing 
these medications are now available for the chronic management of stable COPD. The US 
Food and Drug Administration, recently, approved the combination of budesonide/formoterol 
(160/4.5 µg; Symbicort, AstraZeneca, Sweden) delivered via a pressurized meter dose inhaler 
for maintenance management of stable COPD. The combination also is delivered via dry   powder 
inhaler (Symbicort and Turbuhaler, AstraZeneca, Sweden) but is not approved for use in 
the United States. In this review, we evaluate available data of the efficacy and safety of this 
combination in patients with COPD.
Keywords: inhaled steroid, bronchodilator, β2-agonist, lung function, quality of life, COPD 
exacerbations
Introduction
Chronic obstructive pulmonary disease (COPD) is a debilitating disease that results in 
significant morbidity and mortality. Patients with COPD present with dyspnea, cough, 
sputum production, decreased exercise capacity, and fatigue. COPD not only affects 
the patients physically, but also significantly affects their quality of life. The course 
of COPD is complicated by episodes of acute exacerbations which are associated with 
increased mortality, worse quality of life, and faster lung function decline.1
COPD is a major public health problem in the United States and throughout 
the world. Currently, it is estimated that 12.6 million individuals are affected by 
COPD, and it is the sixth chronic disease condition right after diabetes mellitus and 
asthma in the United States. Moreover, recent data indicate that as high as 45% of 
patients who suffer from COPD are not yet diagnosed. COPD is also a major cause 
of mortality. Currently, COPD results in about 120,000 deaths in the United States 
and is the fourth leading cause of death.2 Significant preventive efforts in control 
of hypertension and hypercholesterolemia resulted in reduced relative mortality of International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
358
Sharafkhaneh et al
cardiovascular diseases, whereas the mortality due to COPD 
has been on the rise.3 An estimation of $42.6 billion   dollars 
are spent on COPD in the United States. The majority of 
these costs are related to exacerbations resulting from this 
disease.4
Physiologically, COPD is characterized by expiratory 
airflow limitation that is partially reversible.5 This airflow 
limitation results in hyperinflation which causes progressive 
dyspnea and exercise limitation. This results in a decline in 
physical activity causing worsening of respiratory status due 
to deconditioning.6 Pathologically, COPD is   characterized 
by emphysema, small airway wall thickening, mucous 
metaplasia, occlusion of small airways with inflammatory 
mucus, and mucous gland hypertrophy and hyperplasia 
in large airways.7–9 Various inflammatory cells including 
  macrophages, neutrophils, and CD8 T lymphocytes are 
increased in lungs of patients with COPD.7
Current management guidelines consider COPD as a 
“preventable and treatable” disease.5 The American Thoracic 
Society/European Respiratory Society outlines clear goals 
for the management of patients with COPD.5 Treatment goals 
include the need to improve symptoms, exercise capacity, 
and quality of life and reduce complications including exac-
erbations, hospitalizations, and mortality. Smoking   cessation 
clearly slows down lung function decline and prolongs life 
in COPD, whereas other preventive measures including 
influenza and pneumococcal vaccinations may affect vari-
ous outcomes positively in patients with COPD. Long-term 
oxygen therapy in COPD patients with resting hypoxemia 
also reduces mortality.5,10 Although current pharmacologi-
cal interventions can improve symptoms,   quality of life, and 
exercise tolerance, none have been shown to alter the natural 
history of this disease by reducing the decline in lung function 
or reducing mortality.
Bronchodilators are the main stay of therapy for symp-
tomatic COPD. Inhaled long-acting agents are in the forefront 
of COPD pharmacotherapy.5 In contrast, the role of inhaled 
corticosteroids (ICSs) in COPD is more controversial. Cur-
rent guidelines recommend use of ICS in COPD patients with 
severe disease and in those with history of exacerbations. 
In the past few years, the US Food and Drug Administra-
tion (FDA) approved combination therapies of long-acting 
β2-agonist (LABA) and ICS. One of the available combina-
tions includes formoterol (LABA) and budesonide (ICS; 
BFC) (Symbicort™, AstraZeneca, Sweden) administered in 
a metered dose inhaler twice daily for patients with stable 
COPD. The efficacy and safety data of this combination in 
patients with COPD are reviewed.
Pharmacology
Formoterol
Formoterol is a LABA which is currently approved for the 
twice-daily maintenance therapy of COPD. The pharmaco-
logic effects of β2-agonists, including formoterol are at least 
partly attributable to their ability to activate intracellular ade-
nylyl cyclase, which stimulates the conversion of   adenosine 
triphosphate to cyclic adenosine monophosphate (cAMP) 
in bronchial smooth muscle cells.11 Increased cAMP causes 
relaxation of the smooth muscle and results in bronchodila-
tation. The bronchodilator response to a given β2-agonist is 
determined by the amount of the drug in the vicinity of the 
β2-adrenergic receptor, the degree of which depends on the 
lipophilicity and chemical structure of the drug.12 The intrin-
sic efficacy of a β2-agonist has also an important role in 
determining the clinical response to these agents.13
Formoterol, unlike other bronchodilators, has physiochem-
ical properties that provide a rapid onset and long duration of 
action. The lipophilicity of formoterol, like   salmeterol, allows 
it to penetrate and be stored in   smooth-muscle cell mem-
branes, resulting in a long duration of bronchodilatory action. 
Formoterol also has hydrophilic properties like albuterol, 
which enables it to access and activate the β2-receptor rapidly 
and exert a rapid onset of action.14   Furthermore, in contrast 
to other existing β2-agonists, formoterol has a very high 
intrinsic efficacy at the β2-receptor.
Formoterol has plasma protein binding of   approximately 
60% in in vitro studies and is metabolized primarily through 
direct glucuronidation.15 In healthy volunteers who received 
high-dose formoterol via the Aerolizer device, Cmax of 
formoterol was observed within 5 minutes of dosing in the 
majority of subjects, indicating that formoterol is rapidly 
absorbed from the large and small airways after inhalation. 
Some subjects had additional increase in plasma levels 
between 3 hours and 6 hours postdose, possibly due to 
enterohepatic recirculation of the drug. The mean terminal 
half-life was 10 hours.16
Budesonide
Budesonide is an anti-inflammatory synthetic ICS. It is a non-
halogenated corticosteroid that exhibits potent   glucocorticoid 
activity and weak mineralocorticoid activity. Budesonide 
is provided as the mixture of 2 epimers (22R and 22S). 
Corticosteroid actions in the human body are mediated by 
the glucocorticoid receptor (GR). This receptor is found 
in the cytoplasm of most cell types.17 Corticosteroids like 
budesonide have a wide range of inhibitory activities against 
many cell types, including lymphocytes, eosinophils, mast International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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cells, neutrophils, and macrophages. It is also active against 
mediators involved in allergic-mediated inflammation and 
nonallergic-mediated inflammation, such as cytokines, his-
tamine, and leukotrienes.18 In vitro evidence suggests that 
budesonide may phenotypically alter alveolar macrophages 
and reduce histamine release from basophils. It also seems 
to inhibit monocyte-mediated cytotoxicity and eosinophil 
activation.
Budesonide has a high topical potency and a low systemic 
bioavailability. The relative affinity of budesonide for the GR is 
higher compared with previously developed inhaled steroids.18 
In standard in vitro tests and animal models, budesonide was 
found to have an approximately 200-fold higher affinity for 
the GR and a 1,000-fold higher topical anti-inflammatory 
potency than cortisol. Inhaled budesonide is a good medium 
of drug delivery as the compound is a moderately lipophilic 
agent with rapid uptake into airway mucosa.18
Tests performed showed that after oral administration of 
budesonide in healthy adults, the peak plasma concentration 
was reached within approximately 1–2 hours. Budesonide 
deposited in the oropharynx at the time of inhalation is 
assumed to be swallowed and eventually absorbed from 
the gastrointestinal tract. However, because of extensive 
first-pass elimination of oral budesonide (approximately 
85%–90%), very little drug is systemically absorbed. In 
vitro studies with human liver homogenates indicate that 
budesonide is rapidly and extensively metabolized by the 
cytochrome P450 system.18 The resulting major metabo-
lites of budesonide are 16α-hydroxyprednisolone and 
6β-hydroxybudesonide. These metabolites have GR activity 
which is only 1% or less than that of the parent drug and are 
hence not potent.
Budesonide has a high affinity for the lung increasing its 
usefulness as an inhaled medication. A study that used the 
isolated perfused rat lung model demonstrated that a sub-
stantial fraction of budesonide present in the lungs is bound 
to tissue components and is retained for an extended time 
period.19 It seems that budesonide fatty acid conjugates are 
formed and retained in the lung on inhalation.
Budesonide is primarily excreted as metabolites in the 
urine and feces. The renal elimination of unchanged budes-
onide is low because of its extensive biotransformation in the 
liver. The terminal elimination half-life of budesonide after 
inhalation is approximately 2.3 hours in children 3–6 years 
of age with asthma.18
Overall, the pharmacokinetic profile of inhaled budes-
onide allows for a long duration of local therapeutic effects 
in the lungs with minimal systemic exposure.
Combination of budesonide  
and formoterol
The combination of ICS with LABA has been used exten  sively 
in asthma but only recently in COPD. Many   questions regard-
ing the use of such combination therapy in COPD remain to 
be answered: Does this combination have   additional benefits 
than either drug used alone? Does one class modify the actions 
of the other? Do they have any synergistic action?
ICS effects on LABA
Much of the information about the interactions between 
ICS and LABA come from the animal models. When rats 
were administered salmeterol systemically for as little as 
1 week, down regulation of pulmonary β2-receptors density, 
as much as 70%, and desensitization of β receptors activity 
were observed.20 However, the addition of corticosteroids 
attenuated this effect.20 Dexamethasone increased the number 
and rate of synthesis of β2-receptors in human lung tissue 
by increasing the transcription of β receptor gene.21 Similar 
results were found when hamster smooth muscle cells were 
treated with triamcinolone acetonide.22
Furthermore, the addition of corticosteroids to LABA 
promotes the transcription of β2-receptor gene leading to 
the upregulation of β2-receptor expression.23,24 The increase 
in density or upregulation of β receptors was also shown 
in in vivo patients taking intra nasal steroids.25 Apart from 
decreased density of  β2-receptors seen with the regular use of 
LABA, inflammatory states are associated with uncoupling 
of β2-receptors leading to decreased efficacy of β-agonists. 
Corticosteroids can reverse this effect; an effect thought to 
be mediated through decreased expression of G-receptor 
kinase 2.26
LABA effects on ICS
In primary human lung fibroblasts and vascular smooth 
muscle cells, salbutamol and salmeterol promoted the translo-
cation of cytosolic GRs into the nucleus as early as 30 minutes 
after treatment of cells and completed within 4 hours.27 This 
activity was similar but less robust compared with application 
of dexamethasone or fluticasone. The BFC activated the GR 
faster than each drug alone when they were applied to human 
bronchial smooth muscle cells.28 Also, there appeared to be a 
synergistic effect of the combination of the drugs in inhibiting 
the proliferation of human bronchial smooth muscle cells. This 
mechanism was likely through stimulation of p21. Interest-
ingly, the effective dosages of budesonide and formoterol 
when used in combination were much lower than required 
when used individually.   Furthermore, formoterol, when added International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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to budesonide in human lung fibroblasts exerted an additive 
effect on the inhibition of interleukin-1β and stimulated 
  production of granulocyte-macrophage colony stimulating 
factor, intercellular adhesion molecule, and vascular cell adhe-
sion molecule.29 This could clinically translate into decreased 
influx of inflammatory cells and better disease control.
In summary, the combination of ICS and LABA appears 
to have multiple beneficial effects, some of which may be 
synergistic. This combination also allows for lower doses of 
each drug, thus potentially decreasing the side effects.
Clinical data
Reducing symptoms is one of the most important goals in man-
agement of COPD patients. Although initiation of therapy is 
based mostly on severity of COPD as defined by forced expira-
tory volume in 1 second (FEV1) and   symptoms,   advancement 
of therapy is mostly on the basis of   improvement of symptoms. 
Four large randomized controlled   trials   evaluated efficacy and 
safety of BFC compared with   budesonide (B), formoterol (F), 
and placebo (PLB) in patients with moderate-to-severe COPD 
and history of at least 1   exacerbation within the 1 year prior 
to screening (Table 1).30–33 Table 2 outlines the detail of the 
4 pivotal studies.
Demographic and baseline characteristics were very 
similar among the 4 trials with mean age of about 63 years, 
mean prebronchodilator FEV1 of about 1–1.1 L (36%–40% 
predicted), and a range of 40–44 pack years of smoking. 
Further, study participants suffered from other comorbid 
conditions including hypertension, abnormal lipid profile, 
cardiac disease, diabetes mellitus, and osteoporosis. As 
shown in Table 2, all studies included changes in FEV1 
from baseline as one of the primary end points,30–33 whereas 
the 2 earlier studies also included COPD exacerbation as a 
coprimary efficacy outcome variable.30,31
The BFC is produced in 2 different delivery devices 
including the dry powder inhaler (DPI) and pressurized 
meter dose inhaler (pMDI). Although large clinical trials 
evaluated efficacy of BFC on both devices, only the pMDI is 
approved by US FDA, whereas the Turbuhaler is approved 
in Europe. Head-to-head trials comparing the 2 delivery 
devices in COPD is lacking. However, in a study of adults and 
adolescents with asthma, BFC pMDI and BFC Turbuhaler 
significantly (P , 0.001 for both) improved AM peak expi-
ratory flow (PEF; the primary efficacy variable) compared 
with budesonide pMDI.34 In a 52-week long-term safety study 
of patients with asthma 12 years of age, BFC pMDI was 
equally well tolerated and as effective as BFC Turbuhaler 
in adults and adolescents with asthma.35 Thus, although the 
comparative data in COPD is lacking, asthma data supports 
effectiveness in both delivery forms.
Efficacy of budesonide/formoterol 
combination
Lung function
Szafranski et al30 reported improvement with BFC in FEV1 
of 15% compared with PLB (P , 0.001), 9% compared 
with B (P , 0.001), and 1% compared with F (P . 0.05). 
Further, the morning and evening PEF increased   significantly 
in BFC arm compared with PLB, B, or F (P , 0.001). 
Calverley et al31 optimized patients with moderate-or-worse 
COPD with 2 weeks of oral steroid (prednisolone 30 mg 
daily), formoterol (Oxis 9 µg two times a day [bid]) and as 
needed terbutaline (Bricanyl 0.5 mg) before randomization 
to the study arms (BFC, B, F, and PLB). FEV1 significantly 
improved with the optimization (0.21 ± 0.32 L). During the 
subsequent postrandomization study period (12 months), 
BFC maintained the improvement in FEV1, whereas the 
other arms (B, F, and PLB) showed significant drop in mean 
postdose FEV1. The difference in mean postdose FEV1 was 
significantly higher in BFC arm compared with PLB (14%), 
B (11%), and F (5%). Similar changes were seen in vital 
capacity and morning PEF. Evening PEF was also higher in 
BFC compared with PLB and B.31
Tashkin et al33 (6-month study) and Rennard et al32 
(12-month study) reported on coprimary end points of 
  predose FEV1 and 1-hour postdose FEV1. In both of these 
studies conducted in the United States, BFC was administered 
in a pMDI. In Tashkin’s study, BFC (320/9 µg bid) increased 
predose FEV1 significantly compared with F, B, and PLB, 
whereas BFC (160/9 µg bid) only increased predose FEV1 sig-
nificantly compared with B and PLB but not F. Furthermore, 
BFC (320/9 µg bid) increased 1-hour postdose FEV1 signifi-
cantly compared with F, B, and PLB, whereas BFC (160/9 µg 
bid) only increased 1-hour postdose FEV1   significantly 
compared with B and PLB but not F.33 In Rennard’s study, 
BFC (320/9 µg bid) increased predose and 1-hour postdose 
Table 1 Major inclusion criteria in pivotal studies of combina-
tion BFC
Age 40 y
Duration of COPD symptoms 2 y
Smoking history 10 y
Prebronchodilator Fev1 (%) #50%
Fev1/vC or Fev1/FvC 70%
exacerbation (requiring systemic steroid  
and/or antibiotics)
1 within 2–12 months   
before the study
Abbreviations:  COPD,  chronic  obstructive  pulmonary  disease;  Fev1,  forced 
expiratory volume in 1 second; FvC, forced vital capacity; vC, vital capacity.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
361
Budesonide/formoterol combination in COPD
FEV1 significantly compared with F and PLB, whereas BFC 
(160/9 µg bid) only increased predose FEV1 significantly 
compared with PLB but not F. Interestingly, on the day of 
randomization, BFC increased FEV1 by 15%–18% and by 
18%–20% at 5 minutes after the dose administration in 
Tashkin and Rennard studies, respectively.32,33 Similarly, at 
the end of the treatment, BFC resulted in 22% improvement 
in FEV1 at 5 minutes postadministration of the study medica-
tion.32 One-hour postdose inspiratory capacity (IC) increased 
significantly with BFC (both dosage strength) compared with 
F, PLB (P , 0.001),32,33 and B.33 Morning and evening PEF 
also significantly improved with BFC (both dosage strengths) 
compared with B, F, and PLB (P , 0.05).33 Thus, BFC, par-
ticularly at the higher dose (320/9 µg bid) improves various 
indices of lung function compared with B, F, or PLB alone 
(Figures 1A and B).
exercise capacity
No published studies are available to describe the effects of 
BFC on exercise capacity in COPD. However, in an abstract, 
Worth et al36 reported the effects of BFC (320/9 µg bid) 
vs F (9 µg bid) and PLB in a randomized, double-blind, 
  placebo-controlled, crossover ( three 1-week treatment and 
1–2 week wash-out periods) study in patients with COPD and 
increased functional residual capacity of 120%. In this study, 
111 patients were randomized and 91 completed the study. 
Study subjects were very similar to COPD patients enrolled 
in the 4 previously described pivotal studies. At 1-hour post-
dose, exercise endurance time at   constant work exercise test 
(75% of peak work capacity) was   significantly longer with 
BFC (517 seconds)   compared with F (448   seconds; mean 
  difference, 68.9   seconds; P = 0.0015) and PLB (412   seconds; 
mean   difference, 105 seconds; P , 0.0001). At 6-hour 
  postdose, the exercise endurance time remained significantly 
longer (although less robust) with BFC   compared with F 
(mean difference, 42.4 seconds; P , 0.05) and PLB (mean 
  difference, 62 seconds; P = 0.0025). At 1-hour postdose 
  iso-time IC (at 2 minutes into exercise) was significantly 
higher in BFC compared with PLB (21%; P , 0.001) and 
showing a trend compared with F (6%; P = 0.063). In   contrast, 
6-hour postdose   iso-time IC (at 2   minutes into exercise) 
was significantly higher in BFC compared with PLB (8%; 
P , 0.02) and F (7%; P , 0.05).36
COPD exacerbations
ICS alone or in combination with LABA reduce exacerba-
tions of COPD. In a meta-analysis of 6 trials which evaluated 
the long-term effects (6 months) of ICS in stable COPD, 
ICS reduced rates of exacerbation by nearly one-third rela-
tive to PLB (relative risk, 0.70; 95% CI, 0.58–0.84).37 The 
4 pivotal studies of BFC evaluated the impact of long-term 
treatments with BFC on exacerbations. It is important to men-
tion that the definition of COPD exacerbation and the patient 
population enrolled in these studies were not   uniform,   and 
these facts have to be taken in consideration when   analyzing 
the results.
In a12-month study of patients with moderate-to-severe 
COPD, Szafranski et al30 compared the effects of BFC 
(320/9 µg bid), B (400 µg bid), F (9 µg bid), or PLB. BFC 
significantly reduced the number of severe exacerbations by 
11% and 23%, and 24% compared with B, F, and PLB, respec-
tively (P values are 0.385, 0.043, and 0.035, respectively). 
Further, BFC compared with PLB significantly reduced the 
number of oral steroid courses used in association with an 
exacerbation (31%; P = 0.027).30
Calverley et al31 studied patients with COPD (GOLD 
stage 3 or 4) with history of exacerbations requiring a course 
of oral corticosteroids and/or antibiotics 2–12 months prior to 
Table 2 Pivotal randomized controlled trials of BFC
Author N Duration, 
months
Age. years Baseline 
FEV1
Smoking history, 
pack/year
Treatment, µg bid 
delivered dose
Delivery 
system
Primary 
end point
Szafranski et al31 812 12 64 0.99 L 
(36%)
44 BFC, 320/9 B, 200  
F, 9 PLB
Turbuhaler Number of severe 
AeCOPD Change  
in Fev1
Calverley et al32 1,022 12 64 0.99 L 
(36%)
39 BFC, 320/9 B, 400  
F, 9 PLB
Turbuhaler Time to first AECOPD 
Change in Fev1
Tashkin et al34 1,704 6 63 1 L 
(40%)
40 BFC, 320/9 BFC,  
160/9 B, 320 + F,  
9 B, 320 F, 9 PLB
pMDI Predose Fev1 
1 h postdose Fev1
Rennard et al33 1,964 12 63 1 L 
(39%)
40 BFC, 320/9 BFC,  
160/9 F, 9 PLB
pMDI Predose Fev1 
1 h postdose Fev1
Abbreviations: pMDI, pressurized metered dose inhaler; BFC, combination of budesonide and formoterol; B, budesonide; F, formoterol; PLB, placebo; Fev1, forced 
expiratory volume in 1 second; AeCOPD, acute exacerbation of COPD.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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the first clinic visit. BFC prolonged time to first   exacerbation 
requiring antibiotics and/or oral corticosteroids and/or hos-
pitalization compared with all other treatments. The risk of 
having an exacerbation with BFC was reduced by 22.7%, 
29.5%, and 28.5% compared with B, F, and PLB, respectively 
(P = 0.006 vs PLB).31 The exacerbation rate with BFC was 
reduced compared with PLB (23.6%) and F (25.5%) but 
not with B alone (13.6%). Neither B nor F affected either 
measures of exacerbation compared with PLB. Furthermore, 
BFC prolonged the time to first course of oral corticosteroids 
as well as the rate of oral corticosteroid courses compared 
with B, F, and PLB, respectively.31
Tashkin et al33 evaluated the effects of twice-daily inha-
lations of BFC (pMDI, 320/9 and 160/9 µg), B (pMDI, 
320 µg) plus F DPI (9 µg), B (pMDI, 320 µg), F (DPI, 
9 µg), or PLB. The number of exacerbations (requiring oral 
  corticosteroids and/or hospitalization) per patient-treatment 
year was   numerically lower (approximately 20%–25%), 
but did not reach the predetermined statistical significance 
level (P  0.060). This result was driven by the category 
of COPD exacerbations requiring treatment with oral 
corticosteroids.33
Rennard et al32 compared the effects of twice-daily 
  inhalations of BFC (pMDI, 320/9 µg), BFC (pMDI, 
160/9 µg), F (DPI, 9 µg), or PLB on exacerbations in 
patients with moderate to very severe COPD. BFC (both 
320/9 and 160/9 µg dosage strengths) significantly pro-
longed time to first exacerbation compared with PLB (P 
# 0.004). BFC (320/9 µg bid) also significantly prolonged 
time to first exacerbation compared with F (P = 0.026). In 
addition, significant reductions in the overall number of 
exacerbations per patient-treatment year were observed 
with BFC (both 320/9 and 160/9 µg dosage strengths) vs 
PLB (37% and 41%, respectively; P , 0.001) and F (25% 
and 29%, respectively; P # 0.004). These reductions were 
driven by exacerbations treated with oral corticosteroids, the 
rate of which was reduced with BFC and PLB, and F.32
The reduction in COPD exacerbation rates observed with 
both BFC dosage strengths beyond the reduction achieved 
with formoterol alone further demonstrates the important 
contribution of budesonide to the combination product 
(Figure 1C). As shown in Figure 1C, the exacerbation rates 
were different between the 2 earlier studies (Szafranski 
et al30 and Calverley et al)31 when compared with the 2 recent 
studies (Tashkin et al33 and Rennard et al)32. Although one 
cannot be sure about the reason for this difference, gradual 
advancement in therapy in last years and more stringent 
exclusion criteria may have changed the study populations. 
A likely reason for lack of statistically significant reduction 
in acute exacerbation of COPD in Tashkin study may relate 
to the shorter duration of this study.
Patient reported outcomes
There have been only few studies that investigated the 
effects of BFC on patient reported outcomes. Most of these 
studies did measure quality of life using the Saint Georges 
Respiratory Questionnaire (SGRQ). In the Tashkin study, 
BFC improved SGRQ total scores compared with the B, 
F, and PLB groups (P # 0.05). These improvements were 
  clinically meaningful (ie, reduction from baseline of 4 
points) for both BFC dosage strengths compared with the 
baseline   values at all assessed time points. The percentage of 
patients in the BFC 320/9 µg and 160/9 µg groups that dem-
onstrated a clinically meaningful decrease (ie, improvement) 
in SGRQ total score from baseline to the end of the treatment 
compared with patients in the PLB group was significant, 
45.5% and 45.4% as opposed to 35% (P , 0.018). Calverley 
et al32 reported maintained quality of life with BFC compared 
with B, F, and PLB. Szafranski et al30 reported significant 
improvement in SGRQ total score with BFC compared with 
PLB (mean difference, 3.9; P = 0.009). In Rennard’s study,32 
the improvement in SGRQ score with BFC (320/9 µg bid) 
compared with PLB and F was statistically significant but 
the difference did not reach clinically meaningful level 
(4-unit reduction).
In the study by Tashkin,33 patients kept a daily diary 
of the cough scores and a reduction was seen in the 
patients on BFC as opposed to the other study groups. 
BFC also improved dyspnea score (breathlessness diary) 
significantly compared with B, F, and PLB (P # 0.044).33 
Furthermore, rescue medication use was significantly 
decreased and   rescue medication-free days were signifi-
cantly increased with the use of BFC compared with B and 
PLB (P , 0.001).33 BFC significantly reduced the use of 
rescue medication by 0.8 inhalations per day compared with 
both B and PLB (both P , 0.001), and by 0.3 inhalations 
per day compared with F (P , 0.05).31 The percentage of 
awakening-free nights is another measure reported by the 
studies evaluating effects of BFC. BFC improved the night-
time awakenings score   compared with PLB – the patients 
on BFC had a mean changes from run-in to the end of 
the treatment in the   night-time awakening score of 0.16 
(P , 0.004) compared with the patients on PLB.31 Tashkin 
et al33 reported improved sleep score and percentage of 
awakening-free nights in the patients using BFC compared 
with PLB (P # 0.029).International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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Acute exacerbations of COPD C
Figure 1 A–C shows the change in lung function and annual AeCOPD rate in pivotal studies of BFC. A) shows the change in predose Fev1 from baseline in different arms 
of Taskin et al34 and Rennard et al33 studies. B) shows the change in postdose Fev1 from baseline in different arms of Taskin et al34 and Rennard et al33 studies. C) shows the 
annual rate of acute exacerbations of COPD (requiring systemic steroid or hospitalization) in 4 pivotal studies of BFC. 
Notes: aSignificant compared with PLB. bSignificant compared with B. cSignificant compared with F. 
Abbreviations: BFC, combination of budesonide and formoterol; B, budesonide; F, formoterol; PLB, placebo; Fev1, forced expiratory volume in 1 second; COPD, chronic 
obstructive pulmonary disease; AeCOPD, acute exacerbation of COPD.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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Thus, in conclusion, the use of BFC may significantly 
improve patient reported outcomes including dyspnea,   quality 
of life, use of rescue inhaler, and symptom-free nights.
Safety end points of budesonide/
formoterol combination
The 4 large pivotal studies of BFC described earlier   evaluated 
the safety of the study medications. These studies did not 
detected clinically meaningful differences among various 
study arms with adverse events (AEs) mostly judged as mild-
to-moderate intensity by the study physicians.
Szafranski et al30 reported similar AE profiles in each 
group with proportionally more patients reporting COPD 
events in the PLB group than in the active treatment groups 
(17%, 13%, 19%, and 26% in the BFC, B, F, and PLB groups, 
respectively). The percent of patients with serious adverse 
events (SAEs) were similar (20% and 22% for PLB and BFC 
arms, respectively). Also similar SAEs per 1,000 treatment 
days were observed between the groups (0.9 and 0.8 for PLB 
and BFC arms, respectively). Further, no clinically important 
inter-group OR differences were identified for ECG measure-
ments. Similarly, Calverley et al31 did not detect major differ-
ences in safety profile in the study, AE profile, SAE numbers, 
and mortality among various study arms. Tashkin et al33 and 
Rennard et al32 reported higher incidence of nasopharyngitis 
(7.3% and 4.9%), oral candidiasis (6% and 1.8%), bronchitis 
(5.4% and 3.5%), sinusists (3.5% and 1.8%), and viral upper 
respiratory tract infection (3.5% and 2.7%) in BFC (320/9 bid) 
and PLB groups, respectively.38 AE-related withdrawals ranged 
between 6.9% and 11.3% in patients receiving BFC (320/9 
bid).32,33 No significant difference was detected in incidence 
of pneumonia between BFC and PLB arms.
Cost effectiveness budesonide/
formoterol combination
Halpin39 reported on cost effective analysis of BFC in patients 
with asthma and COPD. The analysis used data from 2   studies. 
Data from Calverlay et al31 12-month randomized study, indicated 
that greater cost of BFC was offset by lower exacerbations and 
hospitalization. In a modeling study using data from Szafranski’s 
12-month study, Dal Negro et al40 reported that BFC gave a better 
outcome at lower cost compared with monotherapy.
Comparison of BFC with fluticasone/
salmetero combination
The 2 available combination therapies including BFC 
(Symbicort, Astrazeneca) and fluticasone/salmeterol 
combination (Advair, GSK, UK) were compared in few 
small studies. Partridge et al41 studied 442 subjects with COPD 
in a randomized crossover study with 1-week exposure to 
each of the study medications. BFC showed earlier onset of 
action in regard to lung function with greater improvements 
in total morning activity scores. However, the improvement 
in the symptom scores (within 15 minutes) postmedications 
were similar between the 2 combinations.41 Lindberg et al42 
conducted a single dose study comparing BFC with fluti-
casone/salmeterol combination. The BFC improved FEV1 
at 5 minutes more than fluticasone/salmeterol combination 
but the maximum response was not different between the 2 
combinations.42
Questions and future development
Randomized clinical trials clearly show significant effect of 
combination therapy of inhaled steroid and LABA on vari-
ous COPD-related clinical outcomes. However, a major area 
of research is identification of subgroups of COPD subjects 
that will benefit the most from the combination therapy and 
those that may have the most AEs. As formoterol is a fast-
acting bronchodilator, BFC may have potential for use or 
abuse as a rescue medication. BFC is allowed to be used as 
rescue (1 extra dose) in Europe for asthma but not approved 
by US FDA.43,44 Use of BFC as rescue in COPD is not clearly 
established. Further studies to find out how frequently BFC 
is used as rescue and the safety of such use are needed. This 
data is particularly important as the new US FDA warning 
about use of LABA in asthma and the black box warning for 
the available products in the market.45
Summary
Four large randomized trials clearly indicate that in patients 
with moderate or severe COPD who have a history of a 
COPD exacerbation, BFC improves various COPD-related 
outcomes including lung function, health-related quality 
of life, and reduces the incidence of exacerbations com-
pared with the individual components alone or placebo. 
Furthermore, data from 1-year trials demonstrate that the 
long-term use of this combination is safe. Future studies 
need to evaluate the effect of this combination therapy on 
airway inflammatory indices and in patients with milder 
disease.
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